


May 17, 2023



# NeuroRestore ACD856

## Background & data supporting disease modifying effects


Pontus Forsell, PhD, Head of Discovery & Research at AlzeCure Pharma

## Background: Neurotrophins and ACD856, a clinical stage cognitive enhancer with disease modifying potential

- ACD856 is a novel small molecule positive modulator of Trk receptors enhancing the signaling of neurotrophins, such as Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF)
- The neurotrophins has been known for decades to play an essential role in neuronal survival and function as well as in learning, memory and mood
- ACD856 has been tested in a phase 0 micro-dose study, in a phase 1 single ascending dose study and in a phase 1 multiple ascending dose study
- ACD856 demonstrated excellent pharmacokinetic properties and bioavailability. It was safe, well tolerated with good blood-brain-barrier permeability. Quantitative EEG demonstrated evidence of a pharmacological effect in the CNS, suggesting target engagement.
- The role of neurotrophins and the mechanism of action of ACD856 implies that the compound could have disease modifying effects

## ACD856, mechanism of action supports disease modifying potential

- ACD856 is a novel small molecule positive modulator of Trk-receptors enhancing the signaling of neurotrophins such as NGF and BDNF
- The enhanced signaling leads to short term symptomatic effects with long term benefits
- The long-term effects of ACD856 could include improved neuronal function, increased mitochondrial function and improved cognition.



## Results supporting disease modifying effects

- **In vitro**

- Protection against amyloid-beta induced neurotoxicity
- Potentiation of neuronal growth and neurite outgrowth
- Increased levels of BDNF

- **In vivo**



- Improved memory possibly through increased neuroplasticity
- Long term antidepressant-like effect via a potential neuroplastic adaption



# Amyloid toxicity and disease progression


- Key pathological features of the Alzheimer's disease brain:
  - Amyloid plaque
  - Synapse dysfunction
  - Axon withdrawal
  - Mitochondrial dysfunction
- These events are closely correlated with the cognitive dysfunction that is characteristic for Alzheimer's disease.

Preventive, protective or restorative treatment will have a significant impact on disease progression, especially if combined with a symptomatic effect



# Amyloid-beta induced neurotoxicity

## The life and death of a neuron








**Neuronal function**

**Neuroprotective effects of ACD856**

Synaptic dysfunction  
Neurite degeneration  
Neuronal cell death

## ACD856 and amyloid-beta induced neurotoxicity

- Vehicle (DMSO) or  $A\beta_{1-42}$  was added to neurons, with or without ACD856
- The neuronal content of a synaptic protein (SNAP25) was quantified by microscopy



**ACD856 is protective against  $A\beta_{1-42}$ -induced neurotoxicity**

## Results supporting disease modifying effects

- **In vitro**

- Protection against amyloid-beta induced neurotoxicity
- **Potential of neuronal growth and neurite outgrowth**
- Increased levels of BDNF






- **In vivo**

- Improved memory possibly through increased neuroplasticity
- Long term antidepressant-like effect via a potential neuroplastic adaption



## ACD856 and neurite outgrowth

- Neurotrophins like NGF and BDNF are important for neurite outgrowth and neuronal proliferation
- Effects of ACD856 on cell number and neurite outgrowth was studied in immature neuronal-like cells



**ACD856 increase neuronal growth and neurite formation suggesting a potential for neurorestorative effects**

## Results supporting disease modifying effects

- **In vitro**

- Protection against amyloid-beta induced neurotoxicity
- Potentiation of neuronal growth and neurite outgrowth
- **Increased levels of BDNF**

- **In vivo**

- Improved memory possibly through increased neuroplasticity
- Long term antidepressant-like effect via a potential neuroplastic adaption

# The importance of BDNF in brain function and memory

- BDNF stimulates neuroplasticity and synaptic function
- BDNF levels are increased in an activity-dependent manner. Exercise increase BDNF levels and it is believed to be one of the reasons for well-being after training
- Several lines of evidence point to the involvement of BDNF in Alzheimer's disease and in depression
- The BDNF-Val66Met polymorphism is associated with cognitive impairment and worsened amyloid pathology in Alzheimer's disease
- Carriers of ApoE4 and BDNF-Val66Met alleles have increased amyloid-beta pathology compared to non-carriers

## BDNF-Val66Met heterozygotes

*30% reduced BDNF secretion*



- Increased rates of decline in memory
- Increased CSF Tau and p-Tau
- Reduced hippocampal glucose metabolism

**“To date, this is the only genetic factor found to moderate downstream effects of amyloid- $\beta$  levels in autosomal dominant Alzheimer's disease.”**

Bateman et al, Brain, 2016

## Effects of ACD856 on BDNF levels

- Cortical neurons were incubated with ACD856 for 6 hours
- Old animals were administered ACD856 once daily for 4 weeks



**ACD856 significantly increase the levels of BDNF.**  
**BDNF improves synaptic function and cognition**



## Results supporting disease modifying effects

- **In vitro**


- Protection against amyloid-beta induced neurotoxicity
- Potentiation of neuronal growth and neurite outgrowth
- Increased levels of BDNF

- **In vivo**

- **Improved memory possibly through increased neuroplasticity**
- Long term antidepressant-like effect via a potential neuroplastic adaption

## ACD856 and aged-induced memory impairment

- Old animals were used to study effects of ACD856 on age-induced memory impairment
- Two memory tests were performed at one or eleven days after a learning task



**ACD856 improves age-induced memory impairment to a level similar to young animals**



**A single dose of ACD856 can improve the ability to both learn, store and remember information.  
Repeated administration of ACD856 suggest improved neuroplastic adaption leading to better memory**

## Results supporting disease modifying effects

- **In vitro**


- Protection against amyloid-beta induced neurotoxicity
- Potentiation of neuronal growth and neurite outgrowth
- Increased levels of BDNF

- **In vivo**

- Improved memory possibly through increased neuroplasticity
- **Long term antidepressant-like effect via a potential neuroplastic adaption**

## ACD856 and sustained antidepressant-like effects

- Mice were treated with ACD856 once daily for 5 days
- ACD856 was tested for antidepressant-like effect 3, 5 or 7 days after the last dose



**Repeated dosing of ACD856 leads to a sustained antidepressant-like effect lasting up to one week**



## Summary of preclinical results – potential for disease modification

### **ACD856:**

- ✓ Protects against amyloid-beta induced neurotoxicity
- ✓ Enhance neurite outgrowth and neuronal proliferation
- ✓ Increase the levels of BDNF in cortical neurons and in brains of aged mice
- ✓ Improves memory impairment, presumably via increased synaptic function/plasticity
- ✓ Demonstrate a sustained antidepressant-like effect

**ACD856 has several short-term effects leading to memory improvement.  
The presented long-term effects suggest a new potential disease modifying effect.**

## Conclusions

- The preclinical data suggest a new potential use of ACD856
- The effect of ACD856 on BDNF levels are very encouraging and supports that ACD856 can improve learning and memory in multiple ways
- Neuroprotective and neurorestorative effects are add-on effects to the symptomatic effects previously seen with ACD856

**The new presented data introduce a potential for disease modifying treatment to the already established symptomatic effects of ACD856.**

# Acknowledgement

- **Team at Alzecure Pharma**

- Cristina Parrado
- Gunnar Nordvall
- Maria Backlund
- Veronica Lidell
- Azita Rasti
- Sanja Juric
- Märta Dahlström
- Magnus Halldin
- Johan Sandin

- **Karolinska Institutet**

- Prof. Bengt Winblad
- Prof. Maria Eriksdotter
- Assoc. Prof. Sumonto Mitra



Some of the artwork were performed by the use of BioRender.com



AlzeCure Pharma AB  
Karolinska Institutet Novum Science Park  
Hälsovägen 7, 141 57 Stockholm  
Sweden

[www.alzecurepharma.com](http://www.alzecurepharma.com) [info@alzecurepharma.com](mailto:info@alzecurepharma.com)

